INVINCIBLE-3 Study, and 25 patients have been screenedEight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screenedFinal sarcoma data from our first metastatic ...

Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand ...

Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company ™, today announced that ...

Quantum-Si's next-gen protein sequencing tech and growth partnerships show promise, but high costs, financial risks, and ...

Quantum-Si aims to revolutionize protein sequencing amidst technological hurdles, uncertain advancements, and market ...

Highlights,Sanctuary Advisors LLC and other financial entities have expanded their stakes in Quantum-Si.,Quantum-Si’s trading ...

Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Quantum-Si in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst S. Ramakanth expects that the ...

Q4 2024 Earnings Call Transcript March 3, 2025 Quantum-Si incorporated misses on earnings expectations. Reported EPS is ...

Reports Q4 revenue $1.2M, consensus $1.2M. “I am very pleased with how we closed out 2024, delivering our first quarter in excess of $1 million ...

Pre-earnings options volume in Quantum Si is normal with calls leading puts 5:2. Implied volatility suggests the market is anticipating a move ...

Quantum-Si (NasdaqGM:QSI) recently announced its participation in the upcoming AGBT meeting, highlighting its advancements in Next-Generation Protein Sequencing, alongside establishing a Scientific ...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the fourth ...